Trinity Biotech Profit Margin 2006-2019 | TRIB
Current and historical gross margin, operating margin and net profit margin for Trinity Biotech (TRIB) over the last 10 years. Profit margin can be defined as the percentage of revenue that a company retains as income after the deduction of expenses. Trinity Biotech net profit margin as of September 30, 2019 is -31.56%.
|Trinity Biotech Annual Profit Margins
|Trinity Biotech Quarterly Profit Margins
||Medical Products Manufacturing
Trinity Biotech plc, headquartered in Bray, the Republic of Ireland, develops, acquires, manufactures, and markets medical diagnostic products for the clinical laboratory and point-of-care (POC) segments of the diagnostic market worldwide. The company provides two haemostasis product lines, Biopool and Amax, comprising test kits and instrumentation used for the detection of blood disorders. These products are used to detect autoimmune, infectious and sexually transmitted diseases, diabetes and disorders of the blood, liver and intestine. The Company is also a provider of raw materials to the life sciences industry. It also engages in the provision of engineering, financial, and management services, as well as in trading business. Trinity Biotech sells its products through its sales force, as well as through a network of distributors and strategic partners.